Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: A single institution experience

Radiology and Oncology

Volumn 44, Issue 2, 2010, Pages 113-120

  Baur, Martina ^a,b   Preusser, Matthias ^c   Piribauer, Maria ^c   Elandt, Katarzyna ^c   Hassler, Marco ^c   Hudec, Marcus ^d   Dittrich, Christian ^a,b   Marosi, Christine ^c  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Glioblastoma multiforme (GBM); High grade glioma; Hypermethylation; Long term survival; MGMT promoter methylation

Indexed keywords

BISULFITE; DNA; FORMALDEHYDE; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PARAFFIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; DNA EXTRACTION; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MALE; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PROMOTER REGION; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 77952975916     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/v10019-010-0023-y     Document Type: Article

References (45)

1. Velnar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours. Radiol Oncol 2010; 44: 13-18.
2. Kachanov DY, 2, Dobrenkov KV, Shamanskaya TV, 2, Abdullaev RT, 2, Inushkina EV, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466
4. Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol 2007; 82: 133-139 (Pubitemid 46431855)
5. Burton EC, Lamborn KR, Forsyth P, Scott J, ÒCampo J, Uyehara-Lock J, et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 2002; 8: 180-187
6. Steinbach JP, Blaicher HP, Herrlinger U, Wick W, Nägele T, Meyermann R, et al. Surviving glioblastoma for more than 5 years: The patient́s perspective. Neurology 2006; 66: 239-242
7. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002; 62: 6205-6210
8. McLendon RE and Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 2003; 98: 1745-1748
9. Senger D, Cairncross JG, Forsyth PAJ. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype? Cancer J 2003; 9: 214-221
10. Scott JN, Rewcastle NB, Brasher PMA, Fulton D, MacKinnon JA, Hamilton M, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999; 46: 183-188
11. Vertosick FT, Selker RG. Long-term survival after the diagnosis of malignant glioma. A series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 1992; 38: 359-363
12. Salvati M, Cervoni L, Artico M, Caruso R, Gagliardi FM. Long-term survival in patients with supratentorial glioblastoma. J Neurooncol 1998; 36: 61-64
13. Morita M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR. Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neurooncol 1996; 27: 259-266
14. Nieder C, Grosu AL, Astner S, Molls M. Treatment of unresectable glioblastoma multiforme. Anticancer Res 2005; 25: 4605-4610
15. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981- 22981/CE.3. Lancet Oncol 2008; 9: 29-38.
16. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al. Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Rad Oncol Biol Phys 1998; 40: 51-55
17. Vranic A. Antigen expression on recurrent meningioma cells. Radiol Oncol 2010; 44: 107-112
18. Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol 2007; 83: 91-93
19. Hau P, Stupp R, Hegi ME. MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis Markers 2007; 23: 97-104.
20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med 2005; 352: 997-1003.
21. Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, et al. Longterm survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009; 27: 1257-1261
22. Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, et al. Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 2009; 151: 1349-1358
23. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Longterm survival with glioblastoma multiforme. Brain 2007; 130: 2596-2606
24. Balana C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, et al. O6- methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9: 1461-1468
25. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M, Ushio Y. Correlation between promoter hypermethylation of the O6- methylguaninedeoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea- based chemotherapy. Neurosurgery 2004; 54: 349-357
26. Blanc JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004; 68: 275-283
27. Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest 2006; 24: 35-40.
28. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354
29. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neurooncologia (GICNO). Br J Cancer 2006; 95: 1155-1160
30. Hassler M, Seidl S, Fazeny-Doerner B, Preusser M, Hainfellner J, Rössler K, et al. Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genet Cytogenet 2006; 166: 46-55.
31. Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A, et al. MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 2007; 83: 173-179
32. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-1874
33. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006; 24: 4412-4417
34. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Labor Invest 2007; 87: 392-397
35. Aldape KD, Jones G, Wang M, Hegi M, Janzer RC, Stupp R, et al. MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma [abstract]. J Clin Oncol 2009; 27(Suppl), 15S. No.2051.
36. Dehdashti AR, Hegi ME, Regli L, Pica A, Stupp R. New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. Neurosurg Focus 2006; 20: 1-6.
37. Gonzalez-Gomez P, Bello MJ, Arjona D, Lomas J, Alonso ME, De Campos JM, et al. Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 2003; 22: 601-608
38. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010; 6: 39-51.
39. Preusser M, Elezi L, Hainfellner JA. Poor reliability and reproducibility of PCRbased testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol 2008; 27: 388-390
40. Ho DM, Hsu CY, Ting LT, Chiang H. MIB-1 and DNA Topoisomerase II? could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol 2003; 119: 715-722
41. Deb P, Sharma MC, Mahapatra AK, Agarwal D, Sarkar C. Glioblastoma multiforme with long-term survival. Neurol India 2005; 53: 329-332
42. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. J Neurooncol 2009; 95: 301-305
43. Gojkovic Horvat A, Kovac V, Strojan P. Radiotherapy in palliative treatment of painful bone metastases. Radiol Oncol 2009; 43: 213-224
44. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. Am J Neuroradiol 2005; 26: 2466-2474
45. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996; 27: 65-73.